# EDGAR Filing Document

**Accession Number:** 0000315545
**File Stem:** 0001493152-23-009212
**Filing Date:** 2023-3
**Character Count:** 5191
**Document Hash:** 388acc812f113d47406330302574248e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-009212.hdr.sgml**: 20230328

**ACCESSION NUMBER**: 0001493152-23-009212

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230327

**FILED AS OF DATE**: 20230328

**DATE AS OF CHANGE**: 20230328

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Morris Jeffrey Allen
- **CENTRAL INDEX KEY:** 0001959175

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36457
- **FILM NUMBER:** 23766396

**MAIL ADDRESS:**
- **STREET 1:** 1729 TRIANGLE PARK DR.
- **CITY:** MARYVILLE
- **STATE:** TN
- **ZIP:** 37801
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROVECTUS BIOPHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000315545
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 900031917
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10025 INVESTMENT DRIVE
- **STREET 2:** SUITE 250
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37932
- **BUSINESS PHONE:** 865-769-4011

**MAIL ADDRESS:**
- **STREET 1:** 10025 INVESTMENT DRIVE
- **STREET 2:** SUITE 250
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37932

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROVECTUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020417

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZAMAGE DIGITAL IMAGING INC
- **DATE OF NAME CHANGE:** 20011126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPM GROUP INC
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Morris Jeffrey Allen<br><sub>(Last) (First) (Middle)</sub><br>1729 TRIANGLE PARK DRIVE<br><sub>(Street)</sub><br>MARYVILLE, TN 37801<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-27 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 18500000<sup>(1)</sup> | D |  |
| Series D-1 Convertible Preferred Stock | 3806990<sup>(2)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 8% Secured Convertible Promissory Note | 2023-05-05 | 2023-05-05 | Series D-1 Convertible Preferred Stock |  | $2.862 | D |  |

---

### Footnotes:

(1) The reporting person has sole voting and dispositve power over 12,000,000 shares of Common Stock, plus 6,500,000 shares of Common Stock owned through a retirement plan.

(2) The reporting person has sole voting and dispositve power over 3,806,990 shares of Series D-1 Convertible Preferred Stock, convertible into 38,069,900 shares of Common Stock.

(3) The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Convertible Preferred Stock at a price of $2.862 per share on 05/05/2023.

**Signature:** /s/ Jeffrey Allen Morris  
**Date:** 2023-03-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**